Jayasuriya Anula 4

What Happened

• Anula Jayasuriya, a director of Lineage Cell Therapeutics, was granted 125,000 derivative securities on 2026-07-01. The grant is reported at an acquisition price of $0.00 (no cash paid at grant) and is categorized as an award/derivative (transaction code A). This was a grant of equity-linked instruments — not a sale — and does not represent immediately transferable common stock.

Key Details

• Transaction date: 2026-07-01; Form 4 filed: 2026-07-02 (timely).
• Grant: 125,000 derivative shares at $0.00 per share; total reported acquisition value $0.
• Vesting/exercise: Per footnote, the award "will vest and become exercisable" on the earlier of July 1, 2027 or the issuer’s next annual meeting of shareholders, subject to continuous service.
• Shares owned after transaction: Not specified in the provided filing summary.
• No 10b5-1, tax-withholding, or sale activity reported in this filing.

Context

• This is an equity award (derivative) that will only convert to exercisable rights or shares after vesting conditions are met — it is not an immediate sale or open-market purchase. Depending on the award type (options vs. RSUs) and later actions (exercise or sale), tax and market impact will vary. The timely filing suggests routine disclosure of a director compensation award.